Last Updated:
Searching
Create account to add to watchlist!

Health Sciences Acquisitions Corp 2 - HSAQ

  • Commons

    $9.86

    -0.10%

    HSAQ Vol: 39.1K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 201.4M
Average Volume: 22.9K
52W Range: $9.68 - $14.66
Weekly %: -0.10%
Monthly %: +0.10%
Inst Owners: 48

Info

Target: Searching
Days Since IPO: 480
Unit composition:
nan
Trust Size: 12500000.0M

🕵Stocktwit Mentions

T8skmod posted at 2021-11-22T23:33:28Z

$HSAQ Twits Stats Today's Change 25% + 🚀 https://t8sk.com/HSAQ

Tickstocks posted at 2021-11-20T22:46:49Z

$HSAQ Twits Stats Today's Change 25% + 🚀 https://t8sk.com/HSAQ

T8skmod posted at 2021-11-19T21:40:37Z

$HSAQ Twits Stats Today's Change 25% + 🚀 https://t8sk.com/HSAQ

T8skmod posted at 2021-11-18T02:24:53Z

$HSAQ Twits Stats Today's Change 25% + 🚀 https://t8sk.com/HSAQ

Tickstocks posted at 2021-11-15T19:51:24Z

$HSAQ Twits Stats Today's Change 25% + 🚀 https://t8sk.com/HSAQ

T8skmod posted at 2021-11-13T20:04:36Z

$HSAQ Twits Stats Today's Change 25% + 🚀 https://t8sk.com/HSAQ

Last10K posted at 2021-11-12T23:55:17Z

$HSAQ just filed a 10-Q Quarterly Report with 32 sections and 4 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/hsaq/0001213900-21-058679.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=hsaq

cctranscripts posted at 2021-11-12T21:37:28Z

Health Sciences Acquisitions Corp 2 Just Filed Its Quarterly Report: Equity Components ... https://www.conferencecalltranscripts.com/summary/?id=10103966 $HSAQ

risenhoover posted at 2021-11-12T21:26:36Z

$HSAQ / Health Sciences Acquisitions Corp 2 files form 10-Q https://fintel.io/sf/us/hsaq?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2021-11-12T21:19:09Z

$HSAQ 📜 SEC Form 10-Q filed by Health Sciences Acquisitions Corporation 2 https://quantisnow.com/insight/2002732?s=s 45 seconds delayed.

Newsfilter posted at 2021-11-12T21:18:18Z

$HSAQ Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/74385e00aee75ae615aed0499ef21745

Tickstocks posted at 2021-10-26T16:18:34Z

$HSAQ Tweet Stats Today's Change 25% + 🚀 https://t8sk.com/HSAQ

Tickstocks posted at 2021-10-18T16:38:10Z

$HSAQ Tweet Stats Today's Change 25% 🚀 + https://t8sk.com/HSAQ

Tickstocks posted at 2021-10-05T15:40:46Z

$HSAQ Tweet Stats Today's Change 25% 🚀 + https://t8sk.com/HSAQ

Tickstocks posted at 2021-10-01T01:57:15Z

$HSAQ Tweet Stats Today's Change 25% 🚀 + https://t8sk.com/HSAQ

Tickstocks posted at 2021-09-23T06:13:24Z

$HSAQ Tweet Stats Today's Change 25% 🚀 + https://t8sk.com/HSAQ

T8skmod posted at 2021-09-02T05:39:27Z

$HSAQ Tweet Stats Today's Change 25% + https://t8sk.com/HSAQ

T8skmod posted at 2021-08-26T16:13:10Z

$HSAQ Tweet Stats Today's Change 25% + https://t8sk.com/HSAQ

Last10K posted at 2021-08-17T01:01:06Z

$HSAQ just filed a 10-Q Quarterly Report with 27 sections and 4 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/hsaq/0001213900-21-043010.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=hsaq

cctranscripts posted at 2021-08-16T20:39:13Z

Health Sciences Acquisitions Corp 2 Just Filed Its Quarterly Report: Net Income (Loss) pe... https://www.conferencecalltranscripts.com/summary/?id=9779102 $HSAQ

fla posted at 2021-08-16T20:30:53Z

$HSAQ [15s. delayed] filed form 10-Q on August 16, 16:16:33 https://s.flashalert.me/dIIBz

risenhoover posted at 2021-08-16T20:25:58Z

$HSAQ / Health Sciences Acquisitions Corp 2 files form 10-Q https://fintel.io/sf/us/hsaq?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2021-08-16T20:21:59Z

$HSAQ 📜 SEC Form 10-Q filed by Health Sciences Acquisitions Corporation 2 https://quantisnow.com/insight/1674116?s=s 30s delayed.

Newsfilter posted at 2021-08-16T20:20:38Z

$HSAQ Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/eff3a4283114067235a416cdc87868b8

tickeron posted at 2021-08-14T07:23:56Z

What do you think of this? $HSAQ in Uptrend: price may jump up because it broke its lower Bollinger Band on August 9, 2021. View odds for this and other indicators: https://srnk.us/go/2952364

tickeron posted at 2021-07-22T18:20:06Z

This is why Hedge Funds use A.I. $HSAQ's Aroon indicator drops into Downtrend on July 7, 2021. View odds for this and other indicators: https://srnk.us/go/2898108

tickeron posted at 2021-07-18T17:17:29Z

Is this good for your portfolio? $HSAQ's price moved below its 50-day Moving Average on June 23, 2021. View odds for this and other indicators: https://srnk.us/go/2888119

tickeron posted at 2021-07-13T01:50:06Z

Is this good for your portfolio? $HSAQ enters a Downtrend because Momentum Indicator dropped below the 0 level on June 23, 2021. View odds for this and other indicators: https://srnk.us/go/2874231

tickeron posted at 2021-07-06T20:33:49Z

Are the daytraders watching this? $HSAQ's Aroon indicator drops into Downtrend on July 2, 2021. View odds for this and other indicators: https://srnk.us/go/2859026

T8SK1 posted at 2021-07-01T00:31:55Z

$HSAQ Tweet Trends Today's Change 25 % + https://t8sk.com/HSAQ

Management

Officers and Directors Upon consummation of this offering, our board of directors will have six members, four of whom will be deemed “independent” under SEC and Nasdaq rules. Our board of directors will be divided into three classes with only one class of directors being elected in each year and each class serving a three-year term. The term of office of the first class of directors, consisting of Michael Brophy and Stuart Peltz, PHD, will expire at our first annual general meeting. The term of office of the second class of directors, consisting of Carsten Boess and Naveen Yalamanchi, MD, will expire at the second annual general meeting. The term of office of the third class of directors, consisting of Pedro Granadillo and Roderick Wong, MD, will expire at our third annual general meeting. We may not hold an annual general meeting until after we consummate our initial business combination. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our Amended and Restated Memorandum and Articles of Association as it deems appropriate. Our Amended and Restated Memorandum and Articles of Association provide that our directors may consist of a chairman of the board, and that our officers may consist of chief executive officer, president, chief financial officer, executive vice president(s), vice president(s), secretary, treasurer and such other officers as may be determined by the board of directors. Executive Compensation No executive officer has received any cash compensation for services rendered to us. Commencing on the date of this prospectus through the completion of our initial business combination with a target business, we will pay to HSAC 2 Holdings, LLC, a fee of $10,000 per month for providing us with office space and certain office and secretarial services. However, pursuant to the terms of such agreement, we may delay payment of such monthly fee upon a determination by our audit committee that we lack sufficient funds held outside the trust to pay actual or anticipated expenses in connection with our initial business combination. Any such unpaid amount will accrue without interest and be due and payable no later than the date of the consummation of our initial business combination. Other than the $10,000 per month administrative fee, no compensation or fees of any kind, including finder’s fees, consulting fees and other similar fees, will be paid to our initial shareholders or any of the members of our management team, for services rendered prior to or in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). However, such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business combinations as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine their operations. There is no limit on the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in the trust account and the interest income earned on the amounts held in the trust account, such expenses would not be reimbursed by us unless we consummate an initial business combination. 83 After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of a general meeting held to consider our initial business combination, as it will be up to the directors of the post-combination business to determine executive and director compensation. In this event, such compensation will be publicly disclosed at the time of its determination in a Current Report on Form 8-K, as required by the SEC. Director Independence Nasdaq listing standards require that within one year of the listing of our ordinary shares on the Nasdaq Capital Market we have at least three independent directors and that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Our Board of Directors had determined that Pedro Granadillo, Carsten Boess, Stuart Peltz, PHD and Michael Brophy, are “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. We will only enter into a business combination if it is approved by a majority of our independent directors. Additionally, we will only enter into transactions with our officers and directors and their respective affiliates that are on terms no less favorable to us than could be obtained from independent parties. Any related-party transactions must be approved by our audit committee and a majority of disinterested directors. Audit Committee Effective as of the date of this prospectus, we will establish an audit committee of the board of directors, which will consist of Carsten Boess, Pedro Granadillo, and Michael Brophy, each of whom is an independent director. Carsten Boess will serve as chairman of the audit committee. The audit committee’s duties, which are specified in our Audit Committee Charter, include, but are not limited to: • reviewing and discussing with management and the independent registered public accounting firm the annual audited financial statements, and recommending to the board whether the audited financial statements should be included in our Form 10-K; • discussing with management and the independent registered public accounting firm significant financial reporting issues and judgments made in connection with the preparation of our financial statements; • discussing with management major risk assessment and risk management policies; • monitoring the independence of the independent registered public accounting firm; • verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; • reviewing and approving all related-party transactions; • inquiring and discussing with management our compliance with applicable laws and regulations; • pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; • appointing or replacing the independent registered public accounting firm; • determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent registered public accounting firm regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; • establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and • approving reimbursement of expenses incurred by our management team in identifying potential target businesses. 84 Financial Experts on Audit Committee The audit committee will at all times be composed exclusively of “independent directors” who are “financially literate” as defined under the Nasdaq listing standards. The Nasdaq listing standards define “financially literate” as being able to read and understand fundamental financial statements, including a company’s balance sheet, income statement and cash flow statement. In addition, we must certify to Nasdaq that the committee has, and will continue to have, at least one member who has past employment experience in finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results in the individual’s financial sophistication. The board of directors has determined that Carsten Boess qualifies as an “audit committee financial expert,” as defined under rules and regulations of the SEC. Compensation Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a compensation committee of the board of directors consisting of Pedro Granadillo and Carsten Boess, each of whom is an independent director. Pedro Granadillo will serve as chairman of the compensation committee. We will adopt a compensation committee charter, will detail the principal functions of the compensation committee, including: • reviewing and approving on an annual basis the corporate goals and objectives relevant to our President and Chief Executive Officer’s compensation, evaluating our President and Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our President and Chief Executive Officer based on such evaluation; • reviewing and approving the compensation of all of our other executive officers; • reviewing our executive compensation policies and plans; • implementing and administering our incentive compensation equity-based remuneration plans; • assisting management in complying with our proxy statement and annual report disclosure requirements; • approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees; • producing a report on executive compensation to be included in our annual proxy statement; and • reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. The charter will also provide that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC. Director Nominations We do not have a standing nominating committee, though we intend to form a corporate governance and nominating committee as and when required to do so by law or Nasdaq rules. In accordance with Rule 5605(e)(2) of the Nasdaq rules, a majority of the independent directors may recommend a director nominee for selection by the board of directors. The board of directors believes that the independent directors can satisfactorily carry out the responsibility of properly selecting or approving director nominees without the formation of a standing nominating committee. Michael Brophy, Stuart Peltz, PHD, Carsten Boess, and Pedro Granadillo will participate in the consideration and recommendation of director nominees. In accordance with Rule 5605(e)(1)(A) of the Nasdaq rules, all such directors are independent. As there is no standing nominating committee, we do not have a nominating committee charter in place. The board of directors will also consider director candidates recommended for nomination by our shareholders during such times as they are seeking proposed nominees to stand for election at the next annual general meeting (or, if applicable, extraordinary general meeting). Our shareholders that wish to nominate a director for election to the Board should follow the procedures set forth in our Amended and Restated Memorandum and Articles of Association. 85 We have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, the board of directors considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our shareholders. Code of Ethics Effective upon consummation of this offering, we will adopt a code of ethics that applies to all of our executive officers, directors and employees. The code of ethics codifies the business and ethical principles that govern all aspects of our business. Conflicts of Interest Potential investors should be aware of the following potential conflicts of interest: • None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating their time among various business activities. • In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to our company as well as the other entities with which they are affiliated. Our management has pre-existing fiduciary duties and contractual obligations and may have conflicts of interest in determining to which entity a particular business opportunity should be presented. • Our officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business activities similar to those intended to be conducted by our company. • The insider shares owned by our officers and directors will be released from escrow only if a business combination is successfully completed and subject to certain other limitations. Additionally, our officers and directors will not receive distributions from the trust account with respect to any of their insider shares if we do not complete a business combination. Furthermore, our sponsor has agreed that the private shares and private warrants will not be sold or transferred by it until after we have completed our initial business combination. In addition, our officers and directors may loan funds to us after this offering and may be owed reimbursement for expenses incurred in connection with certain activities on our behalf which would only be repaid if we complete an initial business combination. For the foregoing reasons, the personal and financial interests of our directors and executive officers may influence their motivation in identifying and selecting a target business, completing a business combination in a timely manner and securing the release of their shares. Under Cayman Islands law, directors and officers owe the following fiduciary duties: (i) duty to act in good faith in what the director believes to be in the best interests of the company as a whole; (ii) duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose; (iii) directors should not improperly fetter the exercise of future discretion; (iv) duty not to put themselves in a position in which there is a conflict between their duty to the company and their personal interests; and (v) duty to exercise independent judgment. In addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and the general knowledge skill and experience which that director has. As set out above, directors have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing, or to otherwise benefit as a result of their position. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the shareholders, provided that there is full disclosure by the directors. This can be done by way of permission granted in the Amended and Restated Memorandum and Articles of Association or alternatively by shareholder approval at general meetings. 86 Accordingly, as a result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities meeting the above-listed criteria to multiple entities. In addition, conflicts of interest may arise when our board evaluates a particular business opportunity with respect to the above-listed criteria. We cannot assure you that any of the above-mentioned conflicts will be resolved in our favor. Furthermore, most of our officers and directors have pre-existing fiduciary obligations to other businesses of which they are officers or directors. To the extent they identify business opportunities which may be suitable for the entities to which they owe pre-existing fiduciary obligations, our officers and directors will honor those fiduciary obligations. Accordingly, it is possible they may not present opportunities to us that otherwise may be attractive to us unless the entities to which they owe pre-existing fiduciary obligations and any successors to such entities have declined to accept such opportunities. In order to minimize potential conflicts of interest which may arise from multiple corporate affiliations, each of our officers and directors has contractually agreed, pursuant to a written agreement with us, until the earliest of a business combination, our liquidation or such time as he ceases to be an officer or director, to present to our company for our consideration, prior to presentation to any other entity, any suitable business opportunity which may reasonably be required to be presented to us, subject to any pre-existing fiduciary or contractual obligations he might have. The following table summarizes the other relevant pre-existing fiduciary or contractual obligations of our officers and directors: Name of Individual Name of Affiliated Company Entity’s Business Affiliation Roderick Wong, MD RTW Investments, LP Healthcare investment firm Managing Partner Rocket Pharmaceuticals, Inc. Gene therapies for rare diseases Director RTW Venture Fund Limited Publicly listed healthcare investment fund Investment Manager Avidity Biosciences, Inc. RNA-based medicines for serious diseases Director Landos Biopharma, Inc. Oral therapeutics for autoimmune diseases Director Naveen Yalamanchi, MD RTW Investments, LP Healthcare investment firm Partner Rocket Pharmaceuticals, Inc. Gene therapies for rare diseases Director RTW Venture Fund Limited Publicly listed healthcare investment fund Investment Manager Alice Lee, JD RTW Investments, LP Healthcare investment firm Senior Counsel Chief Compliance Officer Stephanie A. Sirota RTW Investments, LP Healthcare investment firm Chief Business Officer RTW Venture Fund Limited Publicly listed healthcare investment fund Director Pedro Granadillo

Holder Stats

1 0
% of Shares Held by All Insider 21.91%
% of Shares Held by Institutions 58.78%
% of Float Held by Institutions 75.28%
Number of Institutions Holding Shares 48

Mutual Fund Holders

Holder Shares Date Reported Value % Out
Price (T.Rowe) Health Sciences Fund 691234 2020-12-30 8854707 3.38
Putnam Global Health Care Fd 680995 2021-02-27 8457957 3.3300000000000005
Blackrock Funds-Health Sciences Opportunity Portfolio 264960 2020-12-30 3394137 1.3
BlackRock Health Sciences Trust II 233344 2020-12-30 2989136 1.1400000000000001
Franklin Strategic Series-Franklin Biotechnology Discove 171600 2021-01-30 2030028 0.84
Putnam Variable Trust-Global Health Care Fund 69005 2020-12-30 883954 0.33999999999999997
Valic Company I-Health Sciences Fd 39862 2021-02-27 495086 0.19
Price (T.Rowe) Equity Series Inc.-Health Sciences Portf 30999 2020-12-30 397097 0.15
John Hancock Fds II-Health Sciences Fund 19166 2021-02-27 238041 0.09
Blackrock Health Sciences Trust 13696 2020-12-30 175445 0.07

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Wellington Management Group LLP 505,435 $5,000,000 0.0% -19.3% 2.472%
2021-11-16 Millennium Management LLC 97,030 $960,000 0.0% +54.0% 0.474%
2021-11-16 Citadel Advisors LLC 259,824 $2,570,000 0.0% +1.7% 1.271%
2021-11-15 Ancora Advisors LLC 5,400 $53,000 0.0% 0 0.026%
2021-11-15 Pura Vida Investments LLC 106,302 $1,050,000 0.0% -1.5% 0.520%
2021-11-15 Berkley W R Corp 108,849 $1,080,000 0.1% +995.2% 0.532%
2021-11-15 Marshall Wace LLP 80,067 $790,000 0.0% 0 0.392%
2021-11-15 Athanor Capital LP 21,757 $220,000 0.0% -42.3% 0.106%
2021-11-12 Weiss Asset Management LP 115,822 $1,150,000 0.0% 0 0.566%
2021-11-12 Wolverine Asset Management LLC 21,719 $210,000 0.0% +27.1% 0.106%
2021-11-12 K2 Principal Fund L.P. 420,349 $4,160,000 0.3% +31.2% 2.055%
2021-11-12 Magnetar Financial LLC 40,627 $400,000 0.0% +19.0% 0.199%
2021-11-09 Basso Capital Management L.P. 10,500 $100,000 0.0% 0 0.051%
2021-11-08 Amitell Capital Pte Ltd 555,270 $5,490,000 3.6% +3.3% 2.715%
2021-08-17 Logos Global Management LP 100,000 $1,020,000 0.1% -66.7% 0.489%
2021-08-17 Millennium Management LLC 63,026 $640,000 0.0% +124.9% 0.308%
2021-08-17 Price T Rowe Associates Inc. MD 810,138 $8,260,000 0.0% -4.7% 3.962%
2021-08-17 Parallax Volatility Advisers L.P. 17,700 $180,000 0.0% 0 0.087%
2021-08-17 ATW Spac Management LLC 157,159 $1,600,000 0.4% 0 0.769%
2021-08-17 Boothbay Fund Management LLC 182,779 $1,860,000 0.1% +1.8% 0.894%
2021-08-17 Citadel Advisors LLC 255,439 $2,610,000 0.0% -1.4% 1.249%
2021-08-13 Affinity Asset Advisors LLC 300,000 $3,060,000 1.1% +33.3% 1.467%
2021-08-13 Murchinson Ltd. 300,000 $3,060,000 1.1% 0 1.467%
2021-08-13 Geode Capital Management LLC 10,388 $110,000 0.0% 0 0.051%
2021-08-13 Amitell Capital Pte Ltd 537,273 $5,480,000 3.4% +12.2% 2.627%
2021-08-11 BlackRock Inc. 797,348 $8,130,000 0.0% -0.3% 3.899%
2021-08-11 Picton Mahoney Asset Management 78,507 $800,000 0.0% 0 0.384%
2021-08-06 Magnetar Financial LLC 34,138 $350,000 0.0% +6.3% 0.167%
2021-05-27 Davidson Kempner Capital Management LP 624,726 $6,960,000 0.1% +46.0% 3.055%
2021-05-18 Davidson Kempner Capital Management LP 624,726 $6,960,000 0.1% +46.0% 3.055%
2021-05-18 Citadel Advisors LLC 259,090 $2,910,000 0.0% +3.6% 1.267%
2021-05-17 Janus Henderson Group PLC 72,805 $820,000 0.0% -57.2% 0.356%
2021-05-17 Nomura Holdings Inc. 25,000 $280,000 0.0% 0 0.122%
2021-05-17 Ikarian Capital LLC 200,000 $2,250,000 0.1% 0 0.978%
2021-05-14 K2 Principal Fund L.P. 64,906 $730,000 0.1% -67.5% 0.317%
2021-05-12 Pura Vida Investments LLC 109,492 $1,230,000 0.0% +9.5% 0.535%
2021-04-12 FNY Investment Advisers LLC 3,000 $33,000 0.0% 0 0.015%
2021-02-16 Davidson Kempner Capital Management LP 427,855 $5,400,000 0.1% -5.5% 2.092%
2021-02-16 Janus Henderson Group PLC 170,276 $2,180,000 0.0% -5.8% 0.833%
2021-02-16 ExodusPoint Capital Management LP 29,800 $380,000 0.0% 0 0.146%
2021-02-12 Magnetar Financial LLC 31,702 $410,000 0.0% +26.8% 0.155%
2021-02-10 Periscope Capital Inc. 109,461 $1,400,000 0.1% -45.3% 0.535%
2021-02-06 Granite Point Capital Management L.P. 48,000 $620,000 0.0% -52.0% 0.235%
2020-11-17 Old Well Partners LLC 14,300 $160,000 0.1% 0 0.070%
2020-11-17 Polar Asset Management Partners Inc. 252,500 $2,780,000 0.0% 0 1.235%
2020-11-17 Logos Global Management LP 300,000 $3,300,000 0.4% 0 1.467%
2020-11-17 Boxer Capital LLC 400,000 $4,400,000 0.2% 0 1.956%
2020-11-16 Rivernorth Capital Management LLC 10,000 $110,000 0.0% 0 0.049%
2020-11-16 Perceptive Advisors LLC 450,000 $4,950,000 0.1% 0 2.200%
2020-11-16 EcoR1 Capital LLC 400,000 $4,400,000 0.3% 0 1.956%
2020-11-16 Boothbay Fund Management LLC 257,253 $2,830,000 0.2% 0 1.258%
2020-11-13 AWM Investment Company Inc. 200,000 $2,200,000 0.4% 0 0.978%
2020-11-12 Sphera Funds Management LTD. 100,000 $1,100,000 0.1% 0 0.489%
2020-11-06 BlackRock Inc. 800,000 $8,800,000 0.0% 0 4.977%
2020-11-06 Granite Point Capital Management L.P. 100,000 $1,100,000 0.1% 0 0.622%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q QUARTERLY REPORT 2021-11-12 https://www.sec.gov/Archives/edgar/data/1814114/000121390021058679/f10q0921_healthsciences.htm
10-Q QUARTERLY REPORT 2021-08-16 https://www.sec.gov/Archives/edgar/data/1814114/000121390021043010/f10q0621_health.htm
10-Q QUARTERLY REPORT 2021-05-17 https://www.sec.gov/Archives/edgar/data/1814114/000121390021027102/f10q0321_healthsciencesacq2.htm
10-K ANNUAL REPORT 2021-03-10 https://www.sec.gov/Archives/edgar/data/1814114/000121390021014633/f10k2020_healthsciences2.htm
SC 13G SCHEDULE 13G 2021-02-16 https://www.sec.gov/Archives/edgar/data/1814114/000121390021009652/ea135662-13ghsac2_health2.htm
10-Q QUARTERLY REPORT 2020-11-05 https://www.sec.gov/Archives/edgar/data/1814114/000121390020035161/f10q0920_healthsciencesacq2.htm
8-K CURRENT REPORT 2020-08-12 https://www.sec.gov/Archives/edgar/data/1814114/000121390020021577/ea125266-8k_healthscience2.htm
3/A 2020-08-10 https://www.sec.gov/Archives/edgar/data/1814114/000121390020021076/xslF345X02/ownership.xml
3/A 2020-08-10 https://www.sec.gov/Archives/edgar/data/1814114/000121390020021074/xslF345X02/ownership.xml
3/A 2020-08-10 https://www.sec.gov/Archives/edgar/data/1814114/000121390020021071/xslF345X02/ownership.xml
3/A 2020-08-10 https://www.sec.gov/Archives/edgar/data/1814114/000121390020021069/xslF345X02/ownership.xml
8-K CURRENT REPORT 2020-08-07 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020770/ea125013-8k_healthsciences2.htm
4 2020-08-06 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020716/xslF345X03/ownership.xml
4 2020-08-06 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020713/xslF345X03/ownership.xml
4 2020-08-06 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020613/xslF345X03/ownership.xml
424B4 PROSPECTUS 2020-08-05 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020382/f424b4_healthsciencescorp2.htm
CERT 2020-08-04 https://www.sec.gov/Archives/edgar/data/1814114/000135445720000378/8A_Cert_HSAQ.pdf
EFFECT 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/999999999520002005/xslEFFECTX01/primary_doc.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020006/xslF345X02/ownership.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020005/xslF345X02/ownership.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020004/xslF345X02/ownership.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020003/xslF345X02/ownership.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020002/xslF345X02/ownership.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020001/xslF345X02/ownership.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020020000/xslF345X02/ownership.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020019999/xslF345X02/ownership.xml
3 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020019998/xslF345X02/ownership.xml
S-1MEF REGISTRATION STATEMENT 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020019997/ea124951-s1mef_health2.htm
8-A12B FORM 8-A12B 2020-08-03 https://www.sec.gov/Archives/edgar/data/1814114/000121390020019874/ea124766-8a12b_healthsci.htm
CORRESP 2020-07-30 https://www.sec.gov/Archives/edgar/data/1814114/000121390020019305/filename1.htm
CORRESP 2020-07-30 https://www.sec.gov/Archives/edgar/data/1814114/000121390020019290/filename1.htm
S-1/A AMENDMENT NO. 2 TO FORM S-1 2020-07-28 https://www.sec.gov/Archives/edgar/data/1814114/000121390020018906/ea124630-s1a2_healthsci.htm
S-1/A AMENDMENT NO. 1 TO FORM S-1 2020-07-24 https://www.sec.gov/Archives/edgar/data/1814114/000121390020018584/ea124377-s1a1_healthsci.htm
S-1 2020-07-17 https://www.sec.gov/Archives/edgar/data/1814114/000121390020017800/fs12020_healthsci2.htm
DRS 2020-06-22 https://www.sec.gov/Archives/edgar/data/1814114/000121390020015488/filename1.htm